British American Tobacco PLC
Change company Symbol lookup
Select an option...
BTI British American Tobacco PLC
AAPL Apple Inc
MBTCU Nocturne Acquisition Corp
AFRM Affirm Holdings Inc
FRONU Frontier Acquisition Corp
ACPS AC Partners Inc
LGIH LGI Homes Inc
GOL Gol Linhas Aereas Inteligentes SA
JPM-L JPMorgan Chase & Co
BZFDW BuzzFeed Equity Warrant Exp 1st Dec 2026 *W EXP 12/01/2026
Go

Consumer Staples : Tobacco | Large Cap Value
Based in United Kingdom
Company profile

British American Tobacco p.l.c. is a United Kingdom-based, multi-category consumer goods company that provides tobacco and nicotine products. The Company invests in building a portfolio of tobacco and nicotine products alongside its traditional tobacco business, including vapour products, tobacco heating products (THPs) and modern oral products. It manages a globally integrated supply chain, and its products are distributed to retail outlets across the world. The Company's segments include the United States, Asia-Pacific and Middle East, Americas and Sub-Saharan Africa, and Europe and North Africa. The Company's products as sold in the United States, including Vuse, Velo, Grizzly, Kodiak, and Camel Snus. Its vapour products are hand-held, battery-powered devices that heat a liquid and creates a vapor to be inhaled. Its THP products do not burn tobacco and no smoke is produced. Its modern oral products are white in color and contain nicotine, water, and other food-grade ingredients.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Closing Price
$37.55
Day's Change
-0.21 (-0.56%)
Bid
--
Ask
--
B/A Size
--
Day's High
37.83
Day's Low
37.52
Volume
(Light)
Volume:
2,469,636

10-day average volume:
3,533,979
2,469,636

Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology

7:00 am ET November 29, 2022 (Globe Newswire) Print
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of NeuropsychopharmacologyGlobeNewswireNovember 29, 2022

DEVON, Pa., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 61st Annual Meeting of the American College of Neuropsychopharmacology, being held December 4-7, 2022 in Phoenix, Ariz. A copy of the poster will be made available on the Zynerba corporate website following the presentation at www.zynerba.com/publications.

Poster Presentation Details
Title:An Open-Label Tolerability and Efficacy Study of ZYN002 (Cannabidiol) Administered as a Transdermal Gel to Children and Adolescents with 22q11.2 Deletion Syndrome (INSPIRE)
Date available:Available online beginning December 5, 2022 for entirety of conference
Live presentation:In-person presentation, Poster Session III, December 7, 2022, 5:30 p.m. - 7:30 p.m. MST
Location:JW Marriott Desert Ridge Resort and Spa, Phoenix, Ariz.



About Zygel


Zygel is the first and only pharmaceutically-manufactured cannabidiol formulated as a patent-protected permeation-enhanced clear gel, designed to provide controlled drug delivery into the bloodstream transdermally (i.e. through the skin). Recent studies suggest that cannabidiol may modulate the endocannabinoid system and improve certain behavioral symptoms associated with neuropsychiatric conditions. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with Fragile X syndrome (FXS), 22q11.2 deletion syndrome (22q) and autism spectrum disorder (ASD). The Company has received orphan drug designation for cannabidiol, the active ingredient in Zygel, from the FDA and the European Commission in the treatment of FXS and the treatment of 22q. Additionally, Zygel has been designated a Fast Track development program for treatment of behavioral symptoms of FXS.

About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. We are committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, 22q11.2 deletion syndrome and autism spectrum disorder. Learn more at www.zynerba.com and follow us on Twitter at @ZynerbaPharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company's expectations, projections and estimates regarding expenses, future revenue, capital requirements, incentive and other tax credit eligibility, collectability and timing, and availability of and the need for additional financing; the Company's ability to obtain additional funding to support its clinical development programs; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company's product candidates may not be replicated or continue to occur in additional trials and may not otherwise support further development in a specified indication or at all; actions or advice of the U.S. Food and Drug Administration, the European Medicines Agency and other foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company's reliance on third parties to assist in conducting pre-clinical and clinical trials for its product candidates; delays, interruptions or failures in the manufacture and supply of the Company's product candidates the Company's ability to commercialize its product candidates; the size and growth potential of the markets for the Company's product candidates, and the Company's ability to service those markets; the Company's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators; the rate and degree of market acceptance of the Company's product candidates; the Company's expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the extent to which health epidemics and other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions; and the extent to which inflation or global instability, including political instability, may disrupt our business operations or our financial condition. This list is not exhaustive and these and other risks are described in the Company's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Zynerba Contact

Peter Vozzo

ICR Westwicke

Office: 443.213.0505

Cell: 443.377.4767

Peter.Vozzo@Westwicke.com



Primary Logo

comtex tracking

COMTEX_419914233/2010/2022-11-29T07:00:01

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.